Palatin doses first patient in Phase 2 study of bremelanotide in obesity

Palatin announced that patient dosing has started for the clinical study designed to enroll up to 60 patients at four trial sites in the United States with the primary endpoint of the trial to demonstrate the safety and increased efficacy of co-administration of bremelanotide with tirzepatide on reducing body weight. Patients will undergo multiple assessments of safety and efficacy to help profile the effectiveness of bremelanotide in treating general obesity as a stand-alone treatment or in conjunction with GLP-1/GIP therapy. Full patient enrollment in this Phase 2 clinical study of BMT-801 is currently expected in Q3 with topline data readout expected in the first half of calendar year 2025.